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Summary
Background Antipsychotic treatment is associated with metabolic disturbance. However, the degree to which metabolic 
alterations occur in treatment with different antipsychotics is unclear. Predictors of metabolic dysregulation are 
poorly understood and the association between metabolic change and change in psychopathology is uncertain. We 
aimed to compare and rank antipsychotics on the basis of their metabolic side-effects, identify physiological and 
demographic predictors of antipsychotic-induced metabolic dysregulation, and investigate the relationship between 
change in psychotic symptoms and change in metabolic parameters with antipsychotic treatment.
Methods We searched MEDLINE, EMBASE, and PsycINFO from inception until June 30, 2019. We included blinded, 
randomised controlled trials comparing 18 antipsychotics and placebo in acute treatment of schizophrenia. We did 
frequentist random-effects network meta-analyses to investigate treatment-induced changes in body weight, BMI, 
total cholesterol, LDL cholesterol, HDL cholesterol, triglyceride, and glucose concentrations. We did meta-regressions 
to examine relationships between metabolic change and age, sex, ethnicity, baseline weight, and baseline metabolic 
parameter level. We examined the association between metabolic change and psychopathology change by estimating 
the correlation between symptom severity change and metabolic parameter change.
Findings Of 6532 citations, we included 100 randomised controlled trials, including 25 952 patients. Median treatment 
duration was 6 weeks (IQR 6–8). Mean differences for weight gain compared with placebo ranged from −0·23 kg 
(95% CI −0·83 to 0·36) for haloperidol to 3·01 kg (1·78 to 4·24) for clozapine; for BMI from −0·25 kg/m² 
(−0·68 to 0·17) for haloperidol to 1·07 kg/m² (0·90 to 1·25) for olanzapine; for total-cholesterol from −0·09 mmol/L 
(–0·24 to 0·07) for cariprazine to 0·56 mmol/L (0·26–0·86) for clozapine; for LDL cholesterol from −0·13 mmol/L 
(−0.21 to −0·05) for cariprazine to 0·20 mmol/L (0·14 to 0·26) for olanzapine; for HDL cholesterol from 0·05 mmol/L 
(0·00 to 0·10) for brexpiprazole to −0·10 mmol/L (−0·33 to 0·14) for amisulpride; for triglycerides from 
−0·01 mmol/L (−0·10 to 0·08) for brexpiprazole to 0·98 mmol/L (0·48 to 1·49) for clozapine; for glucose from 
−0·29 mmol/L (−0·55 to −0·03) for lurasidone to 1·05 mmol/L (0·41 to 1·70) for clozapine. Greater increases in 
glucose were predicted by higher baseline weight (p=0·0015) and male sex (p=0·0082). Non-white ethnicity was 
associated with greater increases in total cholesterol (p=0·040) compared with white ethnicity. Improvements in 
symptom severity were associated with increases in weight (r=0·36, p=0·0021), BMI (r=0·84, p<0·0001), total-
cholesterol (r=0·31, p=0·047), and LDL cholesterol (r=0·42, p=0·013), and decreases in HDL cholesterol (r=−0·35, 
p=0·035).
Interpretation Marked differences exist between antipsychotics in terms of metabolic side-effects, with olanzapine 
and clozapine exhibiting the worst profiles and aripiprazole, brexpiprazole, cariprazine, lurasidone, and ziprasidone 
the most benign profiles. Increased baseline weight, male sex, and non-white ethnicity are predictors of susceptibility 
to antipsychotic-induced metabolic change, and improvements in psychopathology are associated with metabolic 
disturbance. Treatment guidelines should be updated to reflect our findings. However, the choice of antipsychotic 
should be made on an individual basis, considering the clinical circumstances and preferences of patients, carers, 
and clinicians.
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Introduction
Antipsychotics form the mainstay of treatment for patients 
with schizophrenia, but many, especially the second-
generation antipsychotics, are associated with weight 
gain, lipid disturbance, and glucose dysregulation, thereby 
contributing to the development of metabolic syndrome.1 
Approximately a third of people with schizophrenia have 
metabolic syndrome, with prevalence as high as 69% in 
those with chronic illness.2 The prevalence of obesity, 
type 2 diabetes, and hyperc holesterolaemia in people with 
schizophrenia is estimated to be 3–5 times higher than in 
the general population.3 Compared with the general 
population, people with schizophrenia are twice as likely 
to have a diagnosis and die as a consequence of cardio-
vascular disease.4 The mortality gap between people with 
schizophrenia and the general population is growing,5 
suggesting a need for improved understanding of the 
factors underlying cardiovascular disease in this group. 
Although studies have previously examined changes in 
weight with different antipsychotics,6 no study has 
comprehensively examined antipsychotic-induced meta-
bolic change (ie, glucose, cholesterol, and triglyceride 
alterations) using network meta-analysis. Thus, the 
relative degree to which metabolic alterations occur in 
acute treatment with various antipsychotics is unclear. 
Furthermore, which physiological or demographic factors 
predict metabolic dysregulation associated with anti-
psychotics is unknown. Previous studies assessing com-
parative efficacies of various antipsychotics have used 
separate network meta-analyses to examine symptom 
change and change in weight.6 However, to date, no meta-
analysis that has synthesised metabolic and symptom-
change data has been done. Whether an association exists 
between antipsychotic-induced metabolic dysregulation 
and symptom change in patients, as suggested by some, 
but not all previous longitudinal studies,7–9 is unclear. 
We did a network meta-analysis of trials comparing 
antipsychotics in the treatment of schizophrenia, aiming 
to investigate the relative effects of various drugs on body 
weight, body-mass index (BMI), and metabolic measures 
(fasting glucose, total cholesterol, LDL cholesterol, 
HDL cholesterol, and triglycerides). We also did 
bi variate meta-analyses and meta-regression analyses of 
placebo-controlled data to investigate whether baseline 
demo graphic and physiological factors predict the mag-
nitude of antipsychotic-induced metabolic change, and 
whether a relationship exists between metabolic change 
and change in severity of psychotic symptoms during 
antipsychotic treatment.
Methods
Search strategy and selection criteria
We followed the PRISMA10 extension statement for 
network meta-analysis (appendix p 2). We searched 
MEDLINE, EMBASE, and PsycINFO from inception until 
June 30, 2019. Our search strategy is described fully in the 
appendix (p 5), but in brief we used the following search 
terms: (antipsychotic OR [generic/branded antipsychotic 
names]) AND (schizo* OR psychos*) AND (random* or 
‘double blind’). We included randomised double-blind 
trials comparing antipsychotics licensed for the treatment 
of schizophrenia in adults with acute exacerbation of 
schizophrenia or a related disorder (schizoaffective, 
schizophreniform, and delusional disorders). We defined 
acute treatment as 6-weeks’ duration.6 If 6-week data were 
not available, data closest to 6 weeks were selected. Clinical 
Research in context
Evidence before this study
Antipsychotic drug treatment possibly causes glucose 
dysregulation and lipid disturbance, thereby contributing to 
the development of the metabolic syndrome in patients with 
schizophrenia. However, the degree to which metabolic 
alterations occur in patients treated with various antipsychotics 
remains unclear. Furthermore, whether baseline patient 
characteristics can predict metabolic dysregulation is unknown, 
and the association between metabolic change and change in 
psychopathology is uncertain. To address these issues, we 
searched PubMed using the keywords “schizophrenia AND 
antipsychotic AND (glucose OR cholesterol OR triglycerides 
OR metabolic)”, from inception until July 19, 2019, and 
without language restriction. Selection criteria were network 
meta-analyses of randomised blinded trials examining 
antipsychotic treatment of patients with schizophrenia, 
in which outcomes were change in glucose, cholesterol, or 
triglyceride concentrations. Of the 664 studies retrieved, 
1 network meta-analysis was identified, which examined only a 
single parameter (glucose concentrations). No studies examined 
baseline predictors of metabolic change, or the relationship 
between metabolic change and change in psychopathology.
Added value of this study
Our findings show variations in antipsychotics in terms of their 
metabolic side-effects, and identify increasing age, male sex, 
and non-white ethnicity as possible risk factors for 
antipsychotic-induced metabolic dysregulation. Furthermore, 
we identified strong evidence that antipsychotic-associated 
improvements in psychopathology are associated with 
metabolic disturbance.
Implications of all the available evidence
Considering the increased prevalence of metabolic syndrome, 
cardiovascular disease, and cardiovascular mortality in patients 
with schizophrenia, data from this study might be used to inform 
antipsychotic prescribing, especially in the at-risk groups we have 
identified. However, clinical decisions to use preferentially an 
antipsychotic with fewer metabolic side-effects should consider 
that clinical improvement appears to be associated with 
development of these side-effects.
See Online for appendix
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trials registry data relating to papers identified in the 
literature review were included.
Data extraction and processing
Pairs of independent investigators (LV, KB, AA, GH, YM, 
and TP) screened references and extracted study-level 
data, with discrepancies adjudicated by TP. We extracted 
outcome data (expressed as mean and SD, standard 
error, or CIs) for change in body weight (kg), BMI 
(kg/m²), fasting glucose, total cholesterol, LDL 
cholesterol, HDL cholesterol, and triglycerides 
(all mmol/L) from initiation to end of treatment for 
groups who received drugs and placebo separately. Only 
continuous data were collected, not binary outcomes. We 
did not use dose limits because of the scarce  evidence 
that dose influences metabolic dysregulation.11 For multi-
group studies re porting several doses of an antipsychotic, 
a summary value for a given metabolic parameter for all 
doses was calculated using formulae from the Cochrane 
Handbook (appendix p 5).12 Because paliperidone is the 
active metabolite of risperidone,13 data for these drugs 
were combined as previously described.14 We also 
extracted publication year; total symptom change (mean 
variance, measured using the Positive and Negative 
Syndrome Scale [PANSS] or Brief Psychiatric Rating 
Scale [BPRS]); baseline weight and baseline metabolic 
parameter level; study duration; anti psychotic drug; 
study population (first-episode psy chosis, multi-episode 
schizophrenia, treatment-resistant schizophrenia, or 
older adults); age; gender; and ethnicity. Authors were 
contacted to request unreported data.
Data analysis
Pairwise meta-analysis
All analyses were done in R (version 3.5.1). For pairwise 
comparisons informed by ten or more studies, we 
synthesised data in a meta-analysis using a random-
effects model in the metafor package (version 2.1–0). We 
investigated the heterogeneity of treatment effects 
visually by inspecting forest plots, alongside monitoring 
of τ (SD of random effects) and the I² statistic. To 
visualise hetero geneity, prediction intervals were 
included in forest plots. Small study effects and 
publication bias were assessed by visual inspection of 
contour-enhanced funnel plots and using Egger’s test.
Assessment of the transitivity assumption
Transitivity is the key underlying assumption of network 
meta-analysis.16 To assess this assumption, we examined 
the distribution of possible effect modifiers across 
treat ment comparisons. Potential effect modifiers included 
age, sex, ethnicity, and body weight.17–19
Network meta-analysis
We fitted random-effects frequentist network meta-
analyses, in which we assumed a common random-effects 
SD (τ) for all comparisons in the network. We fitted our 
models in R using netmeta (version 1.0–1).20,21 Metabolic 
change for each parameter and each treatment comparison 
was estimated as mean difference with 95% CIs. We 
avoided dichotomising results as statistically significant or 
not, and instead presented results with CIs to allow 
clinicians to gauge the range of likely effects.22,23 Placebo 
was used as the reference treatment in all forest plots. We 
created league tables to display the relative degree of 
metabolic disturbance for all comparisons among 
antipsychotics. We used P-scores to rank antipsychotics 
on the basis of the degree of metabolic dysregulation.24 
P-scores ranged from 0 to 1, a higher P-score indicating a 
greater degree of metabolic disturbance. To provide an 
overview of results, we generated a heatmap summarising 
ranking of disturbance across all metabolic parameters for 
all antipsychotics. For most parameters, a higher P-score 
indicates a greater increase in that parameter; however, 
because increased HDL cholesterol reduces cardiovascular 
disease risk,25 a higher P-score for this parameter indicates 
a smaller increase.
Assessment of heterogeneity and inconsistency in the network
We assessed network heterogeneity using τ and I² 
statistic. To visualise heterogeneity, we used prediction 
intervals in all forest plots. We assessed the presence of 
network consistency using a global (design-by-treatment 
inconsistency model) and a local method (back 
calculation).26,27
Risk of bias in network analysis
We assessed risk of bias of individual studies using the 
Cochrane Collaboration’s Tool for Assessing Risk of Bias,28 
classifying risk of bias as high, moderate, or low (appendix 
p 5). We incorporated results into the Confidence in 
Network Meta-Analysis (CINeMA)29,30 application to assess 
the credibility of findings from each network meta-analysis. 
CINeMA grades confidence in results of each treatment 
comparison as high, moderate, low, or very low 
(appendix p 19).
Sensitivity analysis
We hypothesised that the inclusion of various study 
populations might contribute to heterogeneity and 
inconsistency. Thus, we assessed the sensitivity of our 
findings by repeating each network meta-analysis after 
excluding studies examining first-episode psychosis, 
treatment-resistant schizophrenia, and older adults (aged 
65 years and older).
Meta-regression: baseline predictors of 
antipsychotic-associated metabolic alterations
In the general population, body weight, age, sex, and 
ethnicity influence metabolic function.17–19 Therefore, we 
investigated whether these covariates, as well as treatment 
factors, were related to change in metabolic parameters. 
Using the metafor package (version 2.0.0),31 we did meta-
regressions using placebo-controlled data aiming to 
For the Cochrane Handbook see 
http://handbook-5-1.cochrane.
org
For more on CINeMA see 
https://cinema.ispm.unibe.ch
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examine the relationship between antipsychotic-associated 
metabolic change and baseline body weight, baseline level 
of a given parameter (eg, baseline-glucose if examining 
glucose change), age, sex, and ethnicity. In these meta-
regressions, if a study had multiple active groups, 
estimates for each group were merged.12
Assessing the relationship between alterations in metabolic 
parameters and psychopathology
The relationship between metabolic change and psycho-
pathology change is uncertain. To examine whether these 
two outcomes are associated, we did additional bivariate 
meta-analyses using placebo-controlled data. We meta-
analysed the mean difference for change in weight, BMI, 
metabolic parameter, and standardised mean difference 
for change in total symptoms (assessed using PANSS or 
BPRS). Given that within-study correlations between the 
outcomes were not reported, we used a model proposed 
by Riley and colleagues,32 which overcomes this problem, 
using the package metamisc (version 0.2.0).
This study was registered with PROSPERO 
(CRD42019125322, appendix p 5).
Role of the funding source
The funders had no role in study design, data collection, 
data analysis, data interpretation, or writing of the report. 
The corresponding author had full access to all the data 
in the study and had final responsibility for the decision 
to submit for publication.
Results
Of 6512 citations retrieved, 100 (1·5%) studies met the 
inclusion criteria, examining the following: amisulpride, 
aripiprazole, asenapine, brexpiprazole, cariprazine, cloza-
pine, flupenthixol, fluphenazine, haloperidol, iloperidone, 
lura si done, olanzapine, quetiapine, risperidone, palipe-
ridone, sertindole, ziprasidone, and zotepine (appendix 
pp 20–21). The overall sample included 25 952 participants 
(21 124 who were antipsychotic treated, 4828 who were 
placebo treated). The mean age was 35·03 years (SD 6·05), 
14 922 (57·50%) of 25 952 participants were men, 
11 030 (42·5%) were women, 11 537 (63·56%) of 18 151 with 
reported ethnicity were white, and 6614 (36·44%) were 
non-white. Treatment duration was 2–13 weeks (median 
6 weeks [IQR 6–8]). Risk of bias was high for 16% of 
datasets (appendix p 34).
The age and sex of participants were similarly distributed 
across treatment comparisons (appendix p 36). Ethnicity 
and baseline weight differed across treatment com-
parisons, but overall, we deemed the sample similar 
enough to synthesise jointly. We did three pairwise 
comparisons with ten studies or more, all for weight 
change. The results of the meta-analyses and assessment 
of between-study heterogeneity and small study effects 
and publication bias are described in the appendix 
(pp 37–40). We found evidence of small study effects and 
publication bias for the comparison of change in body 
weight with placebo and olanzapine. The corresponding 
contour-enhanced funnel plot showed an absence of 
studies published with statistically insignificant (p>0·10) 
outcomes, and Egger’s regression test suggested funnel 
plot asymmetry (z=2·50, p=0·01). Network graphs are 
shown in figure 1. Forest plots for the mean change in 
metabolic parameter for antipsychotics with placebo as 
the reference treatment are shown in figure 2, and league 
tables comparing antipsychotics for each parameter in the 
appendix (pp 41–46). P-value rankings of antipsychotics 
for all metabolic parameters are shown collectively in a 
heatmap in figure 3 and individually in the appendix 
(pp 47–49). Local assessments of inconsistency are shown 
in the appendix (pp 50–61). CINeMA confidence ratings 
are shown in the appendix (pp 62–87) and were used to 
colour code forest plots in figure 2.
For change in weight, 83 studies compared 18 different 
antipsychotics (18 750 patients) with placebo (4210 patients). 
We did not find evidence of weight gain with ziprasidone, 
haloperidol, fluphenazine, aripiprazole, lurasidone, cari-
prazine, amisulpride, or flupenthixol when compared with 
placebo. We found evidence of weight gain with brexpipra-
zole, risperidone and paliperidone, quetiapine, iloperidone, 
sertindole, olanzapine, zotepine, and clozapine (figure 2; 
appendix p 41). Ranking on the basis of degree of weight 
gain identified haloperidol as the best and clozapine the 
worst (figure 3; appendix p 47). τ was 0·59 kg, considered 
small in the context of the observed antipsychotic-
associated changes, and I² was 71·3% (moderate to 
substantial). The global Q score for inconsistency was 
97·41 (p<0·0001), and significant hotspots of inconsistency 
were identified in five (3·2%) of 154 treatment 
comparisons, including some disagreements between 
direct and indirect evidence (appendix p 50). Certainty 
of evidence was low or very low in 140 (91%) of 
154 comparisons (appendix p 62). A post-hoc analysis 
excluding studies at high risk of bias showed that estimated 
treatment effects were broadly similar, and heterogeneity 
and inconsistency assessments did not materially change 
(appendix pp 88–92).
For change in BMI, 22 studies compared nine different 
antipsychotics (4196 patients) with placebo (900 patients). 
Compared with placebo, no change in BMI was observed 
with haloperidol or aripiprazole. BMI increased with 
lurasidone, risperidone and paliperidone, quetiapine, 
sertindole, clozapine, and olanzapine (figure 2; appendix 
p 42). Ranking on the basis of degree of associated 
BMI alteration identified haloperidol as the best and 
olanzapine the worst (figure 3; appendix p 47). τ was 
0·32kg/m², considered moderate in the context of the 
observed antipsychotic-associated changes, and I² 31·4% 
(low). Inspection of prediction intervals confirmed that 
heterogeneity was low, because for most treatment 
comparisons prediction intervals and CIs led to similar 
conclusions. The global Q score for inconsistency was 
8·93 (p=0·54), and the back-calculation method did not 
provide evidence of network inconsistency (appendix p 53). 
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Figure 1: Network graphs for 
weight, body-mass index, 
total cholesterol, LDL 
cholesterol, HDL cholesterol, 
triglycerides, and glucose
Treatments with direct 
comparisons are linked with a 
line; the thickness of 
connecting lines corresponds 
to the number of trials 
evaluating the comparison.
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(Figure 2 continues on next page)
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Figure 2: Forest plots for mean differences of antipsychotic drugs compared with placebo
Colours indicate the confidence in the evidence for a given comparison: green is high, blue is moderate, yellow is low, and red is very low. Confidence of outcomes was graded using the Confidence in 
Network Meta-Analysis application. Grey lines immediately below each coloured line indicate the PI corresponding to that antipsychotic–placebo comparison. Full results for all treatment comparisons 
are shown in the appendix (pp 41–46). PI=prediction interval.
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Thus, we deemed that no evidence existed for important 
heterogeneity or inconsistency in this network meta-
analysis. Certainty of evidence was low or very low in 18 
(50%) of 36 comparisons (appendix p 69).
For change in total cholesterol, 36 studies compared 
14 different antipsychotics (11 762 patients) with placebo 
(2998 patients). Compared with placebo, we found no 
evidence of change in total cholesterol observed with 
iloperidone, cariprazine, sertindole, ziprasidone, lura-
sidone, brexpiprazole, aripiprazole, risperidone and pali-
peridone, haloperidol, and amisulpride. Total cholesterol 
increased with quetiapine, olanzapine, and clozapine 
(figure 2; appendix p 43). Ranking on the basis of degree of 
associated total cholesterol alteration identified cariprazine 
as the best and clozapine the worst (figure 3; appendix 
p 47). τ was 0·08 mmol/L, considered small in the context 
of the observed antipsychotic-associated changes, and I² 
was 45·1% (moderate). Conclusions drawn from prediction 
intervals and CIs agreed. The global Q score for 
inconsistency was 35·55 (p=0·017). However, out of 
91 treatment comparisons, we identified only a single 
hotspot of inconsistency showing disagreement between 
indirect and direct evidence (appendix p 54). Thus, overall, 
we concluded that heterogeneity and inconsistency were 
not a source of concern in this network meta-analysis. 
Certainty of evidence was low in 65 (71%) of 91 comparisons 
(appendix p 71).
For change in LDL cholesterol, 24 studies compared nine 
different antipsychotics (7439 patients) with placebo 
(2419 patients). Compared with placebo, we found no 
strong evidence of change in LDL cholesterol with 
ziprasidone, lurasidone, risperidone and pali peridone, 
aripiprazole, and brexpiprazole (figure 2). We did observe a 
decrease in LDL cholesterol with cariprazine (figure 2). We 
observed increases in LDL cholesterol with quetiapine and 
olanzapine (figure 2; appendix p 44). Ranking on the basis 
of degree of associated LDL cholesterol alteration defined 
cariprazine as the best and olanzapine the worst (figure 3; 
appendix p 48). τ was 0·03 mmol/L, considered small in 
the context of observed anti psychotic-associated changes. 
The prediction intervals did not change our conclusions 
when compared with CIs, and I² was 16·2% (low). The 
global Q score for inconsistency was 4·46 (p=0·92), and 
although we found some disagreements between direct 
and indirect evidence (appendix p 56), overall, we found no 
evidence of important heterogeneity or inconsistency in 
the network. Certainty of evidence was low in 19 (53%) of 
36 comparisons (appendix p 73).
For change in HDL cholesterol, 22 studies compared ten 
different antipsychotics (7073 patients) with placebo 
(2189 patients). Compared with placebo, we found no 
strong evidence of change in HDL cholesterol observed 
with amisulpride, olanzapine, quetiapine, risperidone and 
paliperidone, lurasidone, cariprazine, or ziprasidone 
(figure 2). HDL cholesterol increased with aripiprazole and 
brexpiprazole (figure 2; appendix p 44). Ranking on the 
basis of degree of associated HDL cholesterol alteration 
defined brexpiprazole as the best and amisulpride the 
worst (figure 3; appendix p 48). τ was 0·03 mmol/L, 
considered medium to large in the context of the observed 
antipsychotic-associated changes, and I² was 52·3% 
(moderate). The global Q score for inconsistency was 
18·96 (p=0·025), and out of 45 treatment comparisons, we 
identified two hotspots of inconsistency, although in both 
Figure 3: Heat map of antipsychotic drugs ranked according to associated degree of alteration in bodyweight, body-mass index, and metabolic parameters
Numbers reflect P-score, which rank antipsychotics on a continuous scale from 0 to 1. A higher P-score indicates a greater increase in the metabolic parameter, 
with the exception of HDL cholesterol, for which a higher P-score indicates a smaller increase. Grey squares indicate that data were not available.
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cases, direct and indirect evidence pointed in the same 
direction (appendix p 57). Certainty of evidence was low or 
very low in 100% of comparisons (appendix p 75).
For change in triglycerides, 34 studies compared 
15 different antipsychotics (10 965 patients) with placebo 
(3021 patients). Compared with placebo, we found no 
strong evidence of change in triglyceride concentrations 
with brexpiprazole, lurasidone, sertindole, cariprazine, 
ziprasidone, aripiprazole, risperidone and paliperidone, 
amisulpride, haloperidol, and iloperidone (figure 2). 
Triglyceride concentrations increased with quetiapine, 
olanzapine, zotepine, and clozapine (figure 2; appendix 
p 45). Ranking on the basis of degree of associated 
triglyceride alteration identified brexpiprazole as the best 
and clozapine the worst (figure 3; appendix p 48). τ was 
0·07 mmol/L, considered small in the context of the 
observed antipsychotic-associated changes, and I² was 
42·6% (moderate). The global Q score for inconsistency 
was 45·07 (p<0·0001), but out of 105 treatment com-
parisons, we only identified four hotspots of inconsistency 
showing disagreement between indirect and direct 
evidence (appendix p 58). Certainty of evidence was low or 
very low in 97 (92%) of 105 comparisons (appendix p 77).
For change in fasting-glucose, 37 studies compared 
16 different antipsychotics (10 681 patients) with placebo 
(3032 patients). Compared with placebo, we found no 
strong evidence change in glucose concentrations with 
amisulpride, asenapine, sertindole, ziprasidone, brex-
piprazole, quetiapine, risperidone and paliperidone, 
aripiprazole, haloperidol, cariprazine, and iloperidone 
(figure 2). Glucose concentrations reduced with lurasidone, 
and increased with olanzapine, zotepine, and clozapine 
(figure 2; appendix p 46). Ranking on the basis of degree of 
associated glucose alteration defined lurasidone as the best 
and clozapine the worst (figure 3; appendix p 48). τ was 
0·18 mmol/L, considered moderate in the context of the 
observed antipsychotic-associated changes, and I² was 
62·7% (moderate). The global Q score for inconsistency 
was 55·58 (p<0·0001), but out of 120 treatment com-
parisons, only one significant hotspot of inconsistency was 
identified with disagreement between indirect and direct 
evidence (appendix p 60). Certainty of evidence was low or 
very low in 103 (86%) of 120 comparisons (appendix p 82).
The sensitivity of our findings for all seven network 
meta-analysis outcomes was assessed by repeating 
analyses after the exclusion of studies examining patients 
with first-episode psychosis (four studies), treatment-
resistant schizophrenia (five studies), and older adults 
(two studies). The findings essentially remained the 
same in all sensitivity analyses (appendix pp 88–97), 
indicating that the inclusion of these studies did not have 
a major influence on results. Assessments of hetero-
geneity and inconsistency were also broadly similar, 
except for LDL cholesterol, for which the global test of 
inconsistency worsened (Q 22·67, p=0·030) and 
triglycerides, for which the global test of inconsistency 
improved (Q 4·53, p=0·98), although local tests of 
Figure 4: Bubble plots for meta-regressions on the effect of baseline 
predictors on antipsychotic-induced changes in fasting-glucose
Each bubble corresponds to a study. The size of the bubble is proportional to 
the sample size. The solid line corresponds to the meta-regression estimate, 
and corresponding 95% CI, indicated by light-green shading.
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inconsistency were materially unchanged (appendix 
p 93).
Greater antipsychotic-induced increases in fasting-
glucose levels were associated with higher baseline 
body-weight (study number [k]=20, z=3·18, 
estimate=0·01 kg−¹ [95% CI 0·00–0·02], p=0·0015; 
figure 4A) and larger proportion of male participants 
(k=25, z=2·64, estimate=0·01 [0·00–0·02], p=0.0082; 
Figure 5: Bubble plots for the associations between change in symptom severity and change in metabolic parameters
Each bubble corresponds to a study. The size of the bubble is proportional to the sample size. The solid line corresponds to the meta-regression estimate, 
and corresponding 95% CI, indicated by light-green shading. SMD=standard mean difference.
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figure 4B). Greater antipsychotic-induced increases 
in total cholesterol were associated with a larger 
propor tion of non-white partici pants (k=22, z=2·05, 
estimate=0·003 [mmol/L]−¹ [0·00–0·01], p=0·040). We 
did not find strong evidence of an association between 
change in weight, BMI, LDL cholesterol, HDL cholesterol, 
and triglycerides with any baseline variables.
Greater improvement in total symptom severity was 
strongly associated with greater increases in body weight 
(figure 5A), BMI (figure 5B), total cholesterol (r=0·31 
[df 29], p=0·047), and LDL cholesterol (figure 5C), and 
with greater reductions in HDL cholesterol (figure 5D). 
We did not find evidence of an association between 
symptom change and changes in triglyceride or glucose 
concentrations.
Discussion
We found that antipsychotics vary markedly in their 
effects on body weight, BMI, total cholesterol, LDL 
cholesterol, HDL cholesterol, triglycerides, and glucose 
concentrations. As expected,6 clozapine and olanzapine 
are, across virtually all parameters, associated with the 
largest degree of metabolic dysregulation. However, for 
several antipsychotics we did not find evidence of an effect 
versus placebo in terms of lipid or glucose measures. 
Interestingly, some of the drugs were shown to perform 
better than placebo on some metabolic measures: for 
instance, when compared with placebo, lurasidone led to 
reductions in glucose, cariprazine to reductions in LDL 
cholesterol, and aripiprazole and brexpiprazole to 
increases in HDL cholesterol. Our meta-analysis is the 
first to examine predictors of antipsychotic-induced 
metabolic change. We found that increased baseline 
bodyweight, male sex, and non-white ethnicity predict 
greater vulnerability to antipsychotic-induced metabolic 
dysregulation, suggesting an overlap between risk factors 
for metabolic disease in the general population and in 
people with antipsychotic-induced metabolic disease. We 
did not observe a relationship between baseline weight 
and magnitude of antipsychotic-induced weight gain, as 
observed in some but not all previous studies.33 The 
discrepancies between our results with some of those 
previously documented might be a consequence of the 
large sample size used in our study, and the restriction of 
our analyses to randomised controlled trials of acute 
treatment (with previous studies examining weight gain 
over prolonged time periods of up to 3 years).33 We also 
showed that improvements in total symptom severity are 
associated with increases in weight, BMI, total cholesterol 
and LDL cholesterol concentrations, and decreases in 
HDL cholesterol concentrations, suggesting that the most 
efficacious antipsychotics are associated with the greatest 
metabolic disturbance. An alternative explanation is that 
metabolic side-effects of antipsychotics are similar and 
that our findings reflect medication compliance, with 
poor medication concordance in some participants 
resulting in a reduction in drug efficacy but also fewer 
metabolic side-effects. If so, perhaps previous trial reports 
of reduced metabolic side-effects of some antipsychotic 
treatments such as aripiprazole were not due to the 
pharmacological properties of the drug, rather to the fact 
that patients did not take the medication. However, when 
we examined data for metabolic changes with aripiprazole 
when concordance was assured via the use of long-acting 
injectable formulation, glucose and lipid alterations with 
aripiprazole treatment were no different from placebo 
treatment, generally in keeping with our findings.34 
Furthermore, the degree of metabolic dysregulation has 
been shown to vary markedly between antipsychotics in 
preclinical studies.35 Our results are also in line with the 
outcomes of previous studies suggesting that more 
efficacious antipsychotics such as olanzapine and 
clozapine are generally associated with weight gain,6 and 
for BMI and weight, our findings support the results from 
previous cohort studies regarding magnitude and 
direction of association.7–9 Our findings do not mean that 
metabolic disturbance is a requirement for efficacy, but do 
highlight that those drugs that are most efficacious tend to 
have the broadest pharmacology, and metabolic effects 
might be due to off-target actions.
We used strict inclusion criteria to obtain a homogenous 
sample. We found no evidence of inconsistency for 
network meta-analyses examining change in BMI, 
LDL cholesterol, and HDL cholesterol, supporting the 
robustness of these outcomes. However, we had some 
concerns regarding inconsistency in the network meta-
analyses of triglycerides and glucose, and more important 
concerns for the network meta-analysis of weight. These 
network meta-analyses showed evidence of global 
inconsistency, although only a small number of local 
hotspots of inconsistency. Inconsistency might have been 
secondary to imbalances in the distribution of some effect 
modifiers observed across comparisons and small study 
effects and publication bias that were noted in pairwise 
meta-analyses. Only a small proportion of studies (16%) 
showed no evidence of bias, and confidence in the evidence 
of the comparisons across all parameters was low or very 
low for 50–100% of treatment com parisons. Notably, the 
most recent and largest network meta-analysis examining 
comparative treatment efficacy of various antipsychotics 
identified the same issue, with confidence of outcomes for 
75% of treatment-comparisons regarded as low or very 
low.6 However, our sensitivity analyses excluding patients 
with first-episode psychosis, treatment-resistant psychosis, 
older adults, and low-quality studies found similar results 
to the overall findings, and measures of inconsistency 
were largely unchanged, supporting the inclusion of these 
data in primary analyses.
In the general population, for every kg increase in body 
weight, cardiovascular disease risk increases by 3·1%,36 
and for every kg/m² increase in BMI, risk of heart failure 
increases by 5–7%,37 and risk of type 2 diabetes increases 
by 8·4%.38 Furthermore, a 1 mmol/L increase in triglyceride 
concentrations corresponds to a 32–76% increased risk 
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of cardiovascular disease.39 Thus, around 6 weeks of 
treatment with antipsychotics such as olanzapine and 
clozapine, which increase body weight by approximately 
3 kg, BMI by approximately 1 kg/m², and triglycerides 
by approximately 1 mmol/L, might lead to important 
increases in cardiovascular disease risk. Hyper trigly-
ceridemia accompanies the development of type 2 
diabetes,40 and we observed increases in fasting glucose of 
1 mmol/L with clozapine. At the onset of psychotic illness 
and before antipsychotic prescription, patients with schizo-
phrenia have impaired glucose and lipid regulation.41–43 
Thus, certain antipsychotics, within a few weeks, might 
worsen metabolic homeostasis in an already susceptible 
cohort, which reinforces international recommendations 
that metabolic monitoring should accompany antipsychotic 
prescription.38 By contrast, aripiprazole was the only 
antipsychotic to show across all parameters either no 
evidence of change or improvement in metabolic 
parameter levels compared with placebo. Brexpiprazole, 
cariprazine, and lurasidone showed improvements in 
some metabolic parameters compared with placebo. The 
metabolic effects of ziprasidone showed no clear difference 
compared with placebo for all parameters assessed. Given 
the risks of cardiovascular and other morbidity associated 
with metabolic dysregulation, these data should be used by 
clinicians and patients as one factor in the choice of an 
antipsychotic, particularly for people with risk factors such 
as increased body weight, being male, and non-white that 
we found predicted increased metabolic dysregulation. 
However, other side-effects should be considered, such as 
extrapyramidal side-effects, 6,13 noting that differences exist 
in efficacy between drugs,6 which should also be factored 
when choosing treatment.
Our findings should also be considered in the context of 
population-based studies showing that patients with 
schizophrenia who receive antipsychotic treatment, 
especially clozapine, have lower all-cause and cardiac 
mortality rates compared with patients who do not receive 
antipsychotic treatment.44 Our observation that sympto-
matic improvement accompanies metabolic dysregulation 
might provide some insight into why, paradoxically, 
cardiovascular mortality improves with treat ments that 
lead to worse metabolic outcomes. Improve ments in 
mental state might result in improved self-care and 
engagement with physical health services, which might 
offset the metabolic risk of a drug. Clozapine and 
olanzapine are among the most effective anti psychotic 
drugs and are also the drugs associated with the highest 
risk of metabolic dysregulation.6 Whether the association 
between symptom improvement and metabolic dysreg-
ulation reflects an intrinsic therapeutic link is unclear. One 
possible explanation is that the antipsychotic receptor 
binding profiles implicated in metabolic dysreg ulation, 
such as serotonin 5-HT2A, histamine H1, and muscarinic 
M3 receptors,13 also play a therapeutic role alongside D2 
dopamine receptor blockade.38 In addition to serotonin, 
histamine, and muscarinic activity, peripheral 
dopa minergic signalling might play a role in defining the 
metabolic profiles associated with different antipsychotics, 
which could explain the various lipid and glucose outcomes 
associated with dopamine receptor antagonists compared 
with partial agonists. However, the central and peripheral 
mechanisms that underlie the effects of antipsychotic 
drugs on metabolic parameters are poorly understood. 
Future pre-clinical work should explore whether peripheral 
receptor binding profiles of different antipsychotics 
explain the drugs’ respective metabolic signatures, and 
whether this can be manipulated to mitigate the metabolic 
side-effects of treatment.
Our analysis had some limitations. Despite attempts 
made to contact authors, we were unable to obtain 
metabolic data for several trials, especially if the study was 
done more than 15 years ago. Thus, our findings are 
mostly restricted to randomised controlled trials of 
recently licensed antipsychotics. Further work is required 
to define the metabolic profiles of older drugs, which will 
better inform prescribing practice. We restricted our 
analyses to randomised controlled trials so that biases 
were controlled for to give the best estimates of drug-
specific effects. However, because randomised controlled 
trials are generally quite short, the duration of treatment 
in the studies included was in the range 2–13 weeks. 
Future network meta-analyses should examine anti-
psychotic-induced metabolic dysregulation in patients 
receiving long-term maintenance therapy. Studies often 
did not report on lifestyle and treatment factors that might 
influence metabolic outcomes, including physical 
comorbidity, alcohol use, smoking, diet, exercise, and 
co-prescription of psychiatric (eg, mood stabilisers) or 
physical health medications (eg, statins or anti-glycaemic 
drugs) that might have influenced metabolic parameters. 
However, randomisation of participants should have 
distributed study participants with these confounders 
equally between groups. Our meta-regression analyses 
were based on study-level data and require replication 
with individual patient data. Studies included in the meta-
analysis often did not report the proportions of various 
non-white ethnic groups; therefore, we were unable to 
examine in greater detail the influence of various 
ethnicities on metabolic outcomes.
In conclusion, marked variations exist in the metabolic 
side-effects of antipsychotics, with olanzapine and 
clozapine showing the worst side-effect profiles. 
Aripiprazole, brexpiprazole, cariprazine, lurasidone, and 
ziprasidone are associated with the best metabolic 
outcomes and these drugs can be considered the safest 
options in those at an increased risk of developing 
metabolic complications. However, clinical decisions to 
use preferentially antipsychotics with fewer metabolic 
side-effects should consider that clinical improvement is 
associated with development of these side-effects. We 
identified increased baseline weight, being male, and non-
white as potential risk factors for antipsychotic-induced 
metabolic disturbance. Treatment guidelines should be 
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updated to reflect differences in metabolic risk, but the 
choice of the treatment intervention should be made on an 
individual patient basis, considering the clinical circum-
stances and preferences of patients, carers, and clinicians.
Contributors
TP formulated the research questions and did the literature search. 
TP, LV, YM, GH, AA, and KB selected the articles and extracted outcome 
data. TP, OE, and RM did the statistical analyses. TP, RM, SN, OE, AC, 
and OH wrote the report. TP had full access to all the data in the study 
and takes responsibility for the integrity of the data and the accuracy of 
the data analysis.
Declaration of interests
ODH reports investigator-initiated research funding from AstraZeneca, 
Autifony, Heptares, Lundbeck, Sunovian, and Roche, and speaker 
meetings organised by BMS, Eli Lilly, Jansenn, Lundbeck, Lyden-Delta, 
Sunovion, and Rand. YM reports grants from the Japan Society for the 
Promotion of Science, Astellas Foundation for Research on Metabolic 
Disorders, the Japanese Society of Clinical Neuropsychopharmacology, 
and the Mochida Memorial Foundation for Medical and Pharmaceutical 
Research; and personal fees from Sumitomo Dainippon Pharma, 
Bracket, Medavante-Prophase, outside of the submitted work. 
All other authors declare no competing interests.
Acknowledgments
This study was funded by the UK Medical Research Council 
(MC-A656-5QD30), Maudsley Charity (666), Brain and Behavior Research 
Foundation, and Wellcome Trust (094849/Z/10/Z) grants to ODH and the 
National Institute for Health Research (NIHR) Biomedical Research 
Centre at South London and Maudsley NHS Foundation Trust and King’s 
College London, and NIHR Oxford Health Biomedical Research Centre at 
Oxford Health NHS Foundation Trust. TP is supported by the NIHR. 
RM is supported by the Wellcome Trust (200102/Z/15/Z). KB is supported 
by the Royal College of Psychiatrists Rosetrees Trust and the Stoneygate 
Trust. OE is supported by the Swiss National Science Foundation (180083). 
AC is supported by the NIHR Oxford Cognitive Health Clinical Research 
Facility (RP-2017-08-ST2-006), NIHR Research Professorship, and a grant 
from the NIHR Oxford Health Biomedical Research Centre 
(BRC-1215-20005).
References
1 Howes OD, Bhatnagar A, Gaughran FP, Amiel SA, Murray RM, 
Pilowsky LS. A prospective study of impairment in glucose control 
caused by clozapine without changes in insulin resistance. 
Am J Psychiat 2004; 161: 361–63.
2 Vancampfort D, Stubbs B, Mitchell AJ, et al. Risk of metabolic 
syndrome and its components in people with schizophrenia and 
related psychotic disorders, bipolar disorder and major depressive 
disorder: a systematic review and meta-analysis. World Psychiatry 
2015; 14: 339–47.
3 Mitchell AJ, Vancampfort D, Sweers K, van Winkel R, Yu W, 
De Hert M. Prevalence of metabolic syndrome and metabolic 
abnormalities in schizophrenia and related disorders—a systematic 
review and meta-analysis. Schizophr Bull 2013; 39: 306–18.
4 Correll CU, Solmi M, Veronese N, et al. Prevalence, incidence and 
mortality from cardiovascular disease in patients with pooled and 
specific severe mental illness: a large-scale meta-analysis of 
3 211 768 patients and 113 383 368 controls. World Psychiatry 2018; 
17: 120.
5 Saha S, Chant D, McGrath J. A systematic review of mortality in 
schizophrenia: is the differential mortality gap worsening over 
time? Arch Gen Psychiatry 2007; 64: 1123–31.
6 Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. Comparative 
efficacy and tolerability of 32 oral antipsychotics for the acute 
treatment of adults with multi-episode schizophrenia: a systematic 
review and network meta-analysis. Lancet 2019; 394: 939–51.
7 Hermes E, Nasrallah H, Davis V, et al. The association between 
weight change and symptom reduction in the CATIE schizophrenia 
trial. Schizophr Res 2011; 128: 166–70.
8 Raben AT, Marshe VS, Chintoh A, Gorbovskaya I, 
Muller DJ, Hahn MK. The complex relationship between 
antipsychotic-induced weight gain and therapeutic benefits: 
a systematic review and implications for treatment. Front Neurosci 
2018; 11: 741.
9 Umbricht DS, Pollack S, Kane JM. Clozapine and weight gain. 
J Clin Psychiatry 1994; 55 (suppl B): 157–60.
10 Moher D, Liberati A, Tetzlaff J, Altman DG, Grp P. 
Preferred reporting items for systematic reviews and meta-analyses: 
the PRISMA statement. J Clin Epidemiol 2009; 62: 1006–12.
11 Simon V, van Winkel R, De Hert M. Are weight gain and metabolic 
side effects of atypical antipsychotics dose dependent? A literature 
review. J Clin Psychiatry 2009; 70: 1041–50.
12 Higgins PT, Green S. Cochrane handbook for systematic reviews of 
interventions version 5.1.0 (updated March 2011). 2011. www.
training.cochrane.org/handbook (accessed June 30, 2019).
13 Kaar SJ, Natesan S, McCutcheon R, Howes OD. Antipsychotics: 
mechanisms underlying clinical response and side-effects and novel 
treatment approaches based on pathophysiology. Neuropharmacology 
2019; published online July 8. DOI:10.1016/j.neuropharm.2019.107704.
14 Cipriani A, Barbui C, Salanti G, et al. Comparative efficacy and 
acceptability of antimanic drugs in acute mania: 
a multiple-treatments meta-analysis. Lancet 2011; 378: 1306–15.
16 Efthimiou O, Debray TP, van Valkenhoef G, et al. GetReal in 
network meta-analysis: a review of the methodology. 
Res Synth Methods 2016; 7: 236–63.
17 Hildrum B, Mykletun A, Hole T, Midthjell K, Dahl AA. Age-specific 
prevalence of the metabolic syndrome defined by the International 
Diabetes Federation and the National Cholesterol Education Program: 
the Norwegian HUNT 2 study. BMC Public Health 2007; 7: 220.
18 Pradhan AD. Sex differences in the metabolic syndrome: implications 
for cardiovascular health in women. Clin Chem 2014; 60: 44–52.
19 Liu J, Hanley AJG, Young TK, Harris SB, Zinman B. 
Characteristics and prevalence of the metabolic syndrome among 
three ethnic groups in Canada. Int J Obesity 2006; 30: 669–76.
20 Rucker G. Network meta-analysis, electrical networks and graph 
theory. Res Synth Methods. 2012; 3: 312–24.
21 Rücker G, Krahn U, König J, Efthimiou O, Schwarzer G. 
netmeta: Network meta-analysis using frequentist methods. 2019. 
https://github.com/guido-s/netmeta (accessed June 30, 2019).
22 Amrhein V, Greenland S, McShane B. Scientists rise up against 
statistical significance. Nature 2019; 567: 305–07.
23 Efthimiou O, White IR. The dark side of the force: multiplicity issues 
in network meta-analysis and how to address them. Res Synth Methods 
2019; published online Sept 2. DOI:10.1002/jrsm.1377.
24 Rucker G, Schwarzer G. Ranking treatments in frequentist network 
meta-analysis works without resampling methods. 
BMC Med Res Methodol 2015; 15: 58.
25 Stone NJ. 2013 ACC/AHA Guideline on the treatment of blood 
cholesterol to reduce atherosclerotic cardiovascular risk in adults: 
a report of the American College of Cardiology/American Heart 
Association Task Force on Practice Guidelines. Circulation 2014; 
129: S46–48.
26 Higgins JP, Jackson D, Barrett JK, Lu G, Ades AE, White IR. 
Consistency and inconsistency in network meta-analysis: 
concepts and models for multi-arm studies. Res Synth Methods 2012; 
3: 98–110.
27 Konig J, Krahn U, Binder H. Visualizing the flow of evidence in 
network meta-analysis and characterizing mixed treatment 
comparisons. Stat Med 2013; 32: 5414–29.
28 Higgins JPT, Altman DG, Gotzsche PC, et al. The Cochrane 
Collaboration’s tool for assessing risk of bias in randomised trials. 
Bmj-Brit Med J 2011; 343: d5928
29 Salanti G, Del Giovane C, Chaimani A, Caldwell DM, Higgins JP. 
Evaluating the quality of evidence from a network meta-analysis. 
PLoS One 2014; 9: e99682.
30 Nikolakopoulou A, Higgins JP, Papakonstantinou T, et al. 
Assessing confidence in the results of network meta-analysis 
(Cinema). bioRxiv 2019; published online April 5. 
DOI:10.1101/597047 (preprint).
31 Viechtbauer W. Conducting Meta-Analyses in R with the metafor 
Package. J Stat Softw 2010; 36: 1–48.
32 Riley RD, Thompson JR, Abrams KR. An alternative model for 
bivariate random-effects meta-analysis when the within-study 
correlations are unknown. Biostatistics 2008; 9: 172–86.
33 Manu P, Dima L, Shulman M, Vancampfort D, De Hert M, 
Correll CU. Weight gain and obesity in schizophrenia: epidemiology, 
pathobiology, and management. Acta Psychiatr Scand 2015; 
132: 97–108.
Articles
www.thelancet.com/psychiatry   Vol 7   January 2020 77
34 Nasrallah HA, Newcomer JW, Risinger R, et al. Effect of aripiprazole 
lauroxil on metabolic and endocrine profiles and related safety 
considerations among patients with acute schizophrenia. 
J Clin Psychiatry 2016; 77: 1519–25.
35 Boyda HN, Tse L, Procyshyn RM, Honer WG, Barr AM. 
Preclinical models of antipsychotic drug-induced metabolic side 
effects. Trends Pharmacol Sci 2010; 31: 484–96.
36 Willett WC, Manson JE, Stampfer MJ, et al. Weight, weight change, 
and coronary heart disease in women. Risk within the ‘normal’ 
weight range. JAMA 1995; 273: 461–65.
37 Kenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heart 
failure. N Engl J Med 2002; 347: 305–13.
38 Cooper SJ, Reynolds GP, Barnes TRE, et al. BAP guidelines on the 
management of weight gain, metabolic disturbances and 
cardiovascular risk associated with psychosis and antipsychotic 
drug treatment. J Psychopharmacol 2016; 30: 717–48.
39 Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a 
cardiovascular risk factor. Am J Cardiol 1998; 81: 7B–12B.
40 Tirosh A, Shai I, Bitzur R, et al. Changes in triglyceride levels over 
time and risk of type 2 diabetes in young men. Diabetes Care 2008; 
31: 2032–37.
41 Pillinger T, Beck K, Gobjila C, Donocik JG, Jauhar S, Howes OD. 
Impaired glucose homeostasis in first-episode schizophrenia: 
a systematic review and meta-analysis. JAMA Psychiatry 2017; 
74: 261–69.
42 Pillinger T, D’Ambrosio E, McCutcheon R, O DH. Is psychosis a 
multisystem disorder? A meta-review of central nervous system, 
immune, cardiometabolic, and endocrine alterations in first-episode 
psychosis and perspective on potential models. Mol Psychiatry 2019; 
24: 776–94.
43 Pillinger T, Beck K, Stubbs B, Howes OD. Cholesterol and 
triglyceride levels in first-episode psychosis: systematic review and 
meta-analysis. Br J Psychiatry 2017; 211: 339–49.
44 Tiihonen J, Lonnqvist J, Wahlbeck K, et al. 11-year follow-up of 
mortality in patients with schizophrenia: a population-based cohort 
study (FIN11 study). Lancet 2009; 374: 620–27.
